The stock of Global Blood Therapeutics Inc. (NASDAQ:GBT) increased by increased by $0.21 on Friday to finish at $31.57, up 0.67 percent. The last five days have seen an average of 901,600 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$11.74. The average number of shares traded over the last 20 days was 1,150,760, while the average volume over the last 50 days totaled 1,137,358.
GBT stock appreciated 19.04% since last month. On 10/01/21, the company’s shares reached a one-month low of $25.11. The stock touched a high of $63.03 on 01/27/21, after rallying from a low of $25.11 in 52 weeks. The price of GBT stock has declined by -27.11% or -$11.74 this year, reaching a new high 10 times. Still, the stock price is down -49.91% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 46 days since Global Blood Therapeutics Inc. (GBT) last reported insider trading activity on Sep 09. On Sep 09, Director Morrison Scott W sold 4,800 shares at $30.21 each. This transaction resulted in the insider making $145,003. On Jun 18, Svoronos Dawn sold 1,609 shares at a price of US$36.54. After the transaction, the insider now owns 3,684 shares. Director Pizzo Philip A. had earlier sold 1,065 shares on Jun 18 for $36.54 a share. The transaction was completed for $38,915.
Beta for the stock is 1.07. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 11.88, the price-to-book (PB) ratio of 6.23.
For the three months ended June 29, Global Blood Therapeutics Inc.’s quick ratio was 6.60, while its current ratio was 7.20, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.47, and the total debt to equity ratio is 0.47. As far as profitability goes, gross margin for the trailing twelve months is 98.30% percent. Based on annual data, it had gross profit of $121.82 million and revenue of $123.8 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GBT’s return on assets (ROA) during the last 12 months has been -39.70%. There was a -43.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -68.60%. ROE has averaged -68.79 in the past year for the broader industry.
According to Global Blood Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $149.27 million in total debt versus $18.09 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $47.56 million, while revenues rose by 33.77% to $39.04 million. It was predicted that Global Blood Therapeutics Inc.’s quarterly earnings would be -$1.12, but it ended up being -$1.19, beating the consensus by 5.90%. EBITDA was -$63.87 million for the quarter. At the end of Global Blood Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 299.21 million, while its total debt was $231.95 million. Equity owned by shareholders amounts to $62.41 million.
Here’s a quick look at Global Blood Therapeutics Inc.’s (GBT) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 65.70%, suggesting the stock is Neutral, with a 62.51% historical volatility rate.
The stochastic %K and %D were 74.36% and 69.95% respectively, while the average true range (ATR) was 1.36. Based on the 14-day stochastic reading of 82.81%, the RSI (14) reading is 62.20%. On the 9-day MACD Oscillator, the stock is at -0.16, and the 14-day reading is at 1.01.
In its analyst report released on October 07, 2021, Jefferies began covering Global Blood Therapeutics Inc. (NASDAQ: GBT). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Global Blood Therapeutics Inc. (GBT) an Overweight rating. GBT is a stock that is recommended for selling by 0 brokerage firms, while 6 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 16 others recommend it as a buy.
What is GBT’s price target for the next 12 months?
The current consensus forecast for the stock is between $30.00 and $138.00, with a median target price of $73.50. In analyzing these forecasts, the average price target given by analysts for Global Blood Therapeutics Inc. (GBT) is $72.25.